Sensorion SA

ALSEN

Company Profile

  • Business description

    Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.

  • Contact

    375, rue du Professeur Joseph Blayac
    Montpellier34080
    FRA

    T: +33 467207730

    https://www.sensorion.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    57

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,852.1036.800.42%
CAC 407,808.1721.12-0.27%
DAX 4024,160.6494.67-0.39%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,998.0656.940.64%
HKSE24,203.3263.750.26%
NASDAQ20,640.3354.800.27%
Nikkei 22539,446.0913.53-0.03%
NZX 50 Index12,676.162.53-0.02%
S&P 5006,268.568.810.14%
S&P/ASX 2008,609.0038.600.45%
SSE Composite Index3,519.659.470.27%

Market Movers